Pre‑treatment hemoglobin levels are an independent prognostic factor in patients with non‑small cell lung cancer

  • Authors:
    • Yue‑Hua Zhang
    • Yuquan Lu
    • Hong Lu
    • Meng‑Wei Zhang
    • Yue‑Min Zhou
    • Xiang‑Lei Li
    • Pin Lv
    • Xiao‑Yan Zhao
  • View Affiliations

  • Published online on: May 16, 2018     https://doi.org/10.3892/mco.2018.1628
  • Pages: 44-49
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

To date, few studies have reported the prognostic value of pre‑treatment hemoglobin levels in patients with non‑small cell lung cancer (NSCLC). In the present study, 416 patients with NSCLC were retrospectively reviewed. Univariate Cox proportional hazards regression analysis demonstrated that patients with normal pre‑treatment hemoglobin (NPHb) levels had a greater chance of surviving for longer period, than did patients with low pre‑treatment hemoglobin (LPHb) levels (HR, 2.05; 95% CI, 1.63‑2.57; P<0.001). After adjustment for age, sex, tumor‑node‑metastasis stage, Karnofsky performance status, lung lobectomy, chemotherapy and radiotherapy, multivariate Cox proportional hazards regression analysis revealed that LPHb was an independent predictor for the poor prognosis of patients with NSCLC (HR, 1.86; 95% CI, 1.47‑2.36; P<0.001). Estimation of the cumulative survival revealed that the overall survival of NPHb patients was significantly higher than that for LBHb patients (P<0.05), independent of whether the patients had received lung lobectomy or chemotherapy treatments. In conclusion, low pre‑treatment hemoglobin levels were demonstrated to be an independent biomarker for poor prognosis in patients with NSCLC.
View Figures
View References

Related Articles

Journal Cover

July-2018
Volume 9 Issue 1

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhang YH, Lu Y, Lu H, Zhang MW, Zhou YM, Li XL, Lv P and Zhao XY: Pre‑treatment hemoglobin levels are an independent prognostic factor in patients with non‑small cell lung cancer. Mol Clin Oncol 9: 44-49, 2018
APA
Zhang, Y., Lu, Y., Lu, H., Zhang, M., Zhou, Y., Li, X. ... Zhao, X. (2018). Pre‑treatment hemoglobin levels are an independent prognostic factor in patients with non‑small cell lung cancer. Molecular and Clinical Oncology, 9, 44-49. https://doi.org/10.3892/mco.2018.1628
MLA
Zhang, Y., Lu, Y., Lu, H., Zhang, M., Zhou, Y., Li, X., Lv, P., Zhao, X."Pre‑treatment hemoglobin levels are an independent prognostic factor in patients with non‑small cell lung cancer". Molecular and Clinical Oncology 9.1 (2018): 44-49.
Chicago
Zhang, Y., Lu, Y., Lu, H., Zhang, M., Zhou, Y., Li, X., Lv, P., Zhao, X."Pre‑treatment hemoglobin levels are an independent prognostic factor in patients with non‑small cell lung cancer". Molecular and Clinical Oncology 9, no. 1 (2018): 44-49. https://doi.org/10.3892/mco.2018.1628